TORVANTA
Other · S&P 500 · data as of 2026-10-05

PTGX stock analysis: PTGX

PTGX (PTGX) is an S&P 500 company in Other. It grades strongest on growth and weakest on value.

The model's view of PTGX · subscribers

Where PTGX ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with PTGX · updated 2026-10-05 · from prices and SEC filings

PTGX price performance

PTGX against the S&P 500, one year
+0%+50%+100%+150%PTGX +116%S&P 500 +18%2025-09-292026-10-05
Year to date+61.0%S&P 500 +14.5% · ahead by 46.5 pts
1 year+116.9%S&P 500 +17.0% · ahead by 99.9 pts
3 years+766.5%S&P 500 +89.3% · ahead by 677.2 pts
5 years+681.7%S&P 500 +91.3% · ahead by 590.4 pts

Total returns with dividends reinvested.

PTGX factor grades

Each grade compares PTGX with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

FValueP/E 137.9x (industry 20.1x)FCF yield 1.4% (industry 6.0%)
A-GrowthRevenue growth +35% (industry +8%)EPS growth +40% (industry +10%)
BProfitabilityOperating margin 20.7% (industry 9.6%)ROIC 13.6% (industry 10.1%)
B+Momentum12-month change +117%From 52-wk high -11%

PTGX in plain numbers

PTGX key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$9.1B
Revenue growth (y/y)+35%
Free-cash-flow yield1.4%
Dividend yieldn/a
Next earnings (expected)2026-11-05
Valuation measures
Market value$9.1B
Enterprise value$8.7B
P/E (trailing)137.9x
Forward P/E (Torvanta estimate)121.6x
PEG (Torvanta estimate)9.05
Price / sales32.3x
Price / book10.8x
EV / revenue30.8x
EV / EBITDA144.9x
Financial highlights
Revenue, last 12 months$282.0M
Net income, last 12 months$82.9M
EPS, last 12 months (GAAP)$1.02
Operating margin20.7%
Net margin29.4%
Return on equity11.0%
Return on invested capital13.6%
Cash$420.1M
Free cash flow, last 12 months$130.6M
Current ratio21.71x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

PTGX earnings trends

Revenue vs earnings
-$44.4M$20.1M$84.5M$149.0M$213.5MSep 2024 Revenue: $4.7MDec 2024 Revenue: $170.6MMar 2025 Revenue: $28.3MJun 2025 Revenue: $5.5MSep 2025 Revenue: $4.7MDec 2025 Revenue: $7.4MMar 2026 Revenue: $56.4MJun 2026 Revenue: $213.5MSep 2024 Net income: -$33.2MDec 2024 Net income: $131.7MMar 2025 Net income: -$11.7MJun 2025 Net income: -$34.8MSep 2025 Net income: -$39.3MDec 2025 Net income: -$44.4MMar 2026 Net income: $3.8MJun 2026 Net income: $162.8MSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: -710.4%Net margin: 77.2%Net margin: -41.2%Net margin: -627.0%Net margin: -834.9%Net margin: -596.8%Net margin: 6.7%Net margin: 76.3%-835%-379%77%■ Revenue ■ Net income ━ Net margin
Earnings per share$-0.7$0.1$0.8$1.5$2.3Sep 2024 EPS (GAAP, diluted): $-0.5Dec 2024 EPS (GAAP, diluted): $2.0Mar 2025 EPS (GAAP, diluted): $-0.2Jun 2025 EPS (GAAP, diluted): $-0.6Sep 2025 EPS (GAAP, diluted): $-0.6Dec 2025 EPS (GAAP, diluted): $-0.7Mar 2026 EPS (GAAP, diluted): $0.1Jun 2026 EPS (GAAP, diluted): $2.3Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Dec 2025 -135%

From the company's 10-Q and 10-K filings with the SEC.

PTGX financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$27.4M$26.6M$60.0M$434.4M$46.0M
Net income-$125.6M-$127.4M-$79.0M$275.2M-$130.1M
EPS (GAAP)$-2.70$-2.61$-1.41$4.23$-2.06
Free cash flow-$109.0M-$108.9M-$70.8M$182.8M$56.1M

PTGX earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-08-05$2.29n/a+3749%+8.0%
2026-05-05$0.05n/a+99%+2.3%
2026-02-25$-0.70-135%-96%+0.9%
2025-11-06$-0.62n/a+1%+3.1%
2025-08-06$-0.55n/a+33%-6.1%
2025-05-06$-0.19-106%-89%-2.3%

About PTGX

HeadquartersNewark, CA
Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Incorporated inDE
Listed onNasdaq
FormerlyProtagonist Therapeutics Inc, Protagonist Inc

From the company's SEC registration record.

Companies similar to PTGX

CompanyMarket valueP/ERevenue growthOperating margin12-month change
PTGX PTGX$9.1B137.9x+35%20.7%+117%
ORI ORI$9.1B8.3x+12%n/a-5%compare
AYI AYI$9.1B20.2x+10%14.5%-13%compare
JXN JXN$9.1B157.5x+15%n/a+33%compare
ESI ESI$9.1B60.5x+13%13.4%+41%
R R$9.0B19.2x+1%n/a+24%
RRC RRC$9.0B10.7x+23%n/a+2%

All Other stock ratings

Frequently asked questions

Is PTGX stock a buy?

Torvanta does not tell individuals what to buy. Its grades for PTGX are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

What is PTGX's P/E ratio?

PTGX trades at about 137.9 times its last 12 months of GAAP earnings reported to the SEC, and about 121.6 times Torvanta's own estimate of the next 12 months.

When does PTGX report earnings next?

Based on its filing history, Torvanta expects PTGX to report around 2026-11-05.

How has PTGX performed against the S&P 500?

Over the past year PTGX returned +116.9%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer